Literature DB >> 7071794

Protriptyline in the treatment of sleep apnoea.

W A Conway, F Zorick, P Piccione, T Roth.   

Abstract

Nine patients with obstructive sleep apnoea were treated with 5 to 20 mg of protriptyline each night for two to 18 months. In four patients, there was dramatic, sustained improvement in symptoms and measured sleep quality and apnoea frequency and duration. There was no improvement in two patients and three developed intolerable side-effects preventing adequate treatment. Apnoea frequency was the only apparent predictor of responsiveness. Those with fewer than 30 episodes of apnoea per hour consistently improved. Only two of four patients with more than 60 episodes per hour improved. These results provide additional evidence that a carefully monitored trial of protriptyline may benefit selected patients with mild to moderate obstructive sleep apnoea.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7071794      PMCID: PMC459244          DOI: 10.1136/thx.37.1.49

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  12 in total

1.  The human tongue during sleep: electromyographic activity of the genioglossus muscle.

Authors:  E K Sauerland; R M Harper
Journal:  Exp Neurol       Date:  1976-04       Impact factor: 5.330

2.  Assessment of acute respiratory failure: cardiac versus pulmonary causes.

Authors:  P M Stevens
Journal:  Chest       Date:  1975-01       Impact factor: 9.410

3.  Progesterone therapy in obese patients with sleep apnea.

Authors:  W C Orr; N K Imes; R J Martin
Journal:  Arch Intern Med       Date:  1979-01

4.  [Pickwickian syndrome: treatment with chlorimipramine].

Authors:  B A Schwartz; J Rochemaure
Journal:  Nouv Presse Med       Date:  1973-06-02

5.  Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4,alpha-dimethyl-meta-tyramine.

Authors:  A Carlsson; H Corrodi; K Fuxe; T Hökfelt
Journal:  Eur J Pharmacol       Date:  1969-03       Impact factor: 4.432

6.  Progesterone for outpatient treatment of Pickwickian syndrome.

Authors:  F D Sutton; C W Zwillich; C E Creagh; D J Pierson; J V Weil
Journal:  Ann Intern Med       Date:  1975-10       Impact factor: 25.391

7.  Sleep apnea: treatment with protriptyline.

Authors:  R W Clark; H S Schmidt; S F Schaal; H Boudoulas; D E Schuller
Journal:  Neurology       Date:  1979-09       Impact factor: 9.910

8.  Surgical management of airway obstructions during sleep.

Authors:  F B Simmons; C Guilleminault; W C Dement; A G Tilkian; M Hill
Journal:  Laryngoscope       Date:  1977-03       Impact factor: 3.325

9.  Sleep-induced apnea syndrome. Prevalence of cardiac arrhythmias and their reversal after tracheostomy.

Authors:  A G Tilkian; C Guilleminault; J S Schroeder; K L Lehrman; F B Simmons; W C Dement
Journal:  Am J Med       Date:  1977-09       Impact factor: 4.965

10.  Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia.

Authors:  H S Schmidt; R W Clark; P R Hyman
Journal:  Am J Psychiatry       Date:  1977-02       Impact factor: 18.112

View more
  13 in total

1.  The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial.

Authors:  Luigi Taranto-Montemurro; Ludovico Messineo; Scott A Sands; Ali Azarbarzin; Melania Marques; Bradley A Edwards; Danny J Eckert; David P White; Andrew Wellman
Journal:  Am J Respir Crit Care Med       Date:  2019-05-15       Impact factor: 21.405

2.  Differential distribution of biogenic amines in the hypoglossal nucleus of the rat.

Authors:  L D Aldes; R C Chronister; L A Marco; J W Haycock; J Thibault
Journal:  Exp Brain Res       Date:  1988       Impact factor: 1.972

3.  Effects of protriptyline on sleep related disturbances of breathing in restrictive chest wall disease.

Authors:  A K Simonds; R A Parker; M A Branthwaite
Journal:  Thorax       Date:  1986-08       Impact factor: 9.139

4.  Desipramine improves upper airway collapsibility and reduces OSA severity in patients with minimal muscle compensation.

Authors:  Luigi Taranto-Montemurro; Scott A Sands; Bradley A Edwards; Ali Azarbarzin; Melania Marques; Camila de Melo; Danny J Eckert; David P White; Andrew Wellman
Journal:  Eur Respir J       Date:  2016-10-06       Impact factor: 16.671

5.  Domiciliary ventilatory support: an analysis of outcome.

Authors:  E H Sawicka; L Loh; M A Branthwaite
Journal:  Thorax       Date:  1988-01       Impact factor: 9.139

6.  Chronic respiratory failure in COPD: is there a place for a respiratory stimulant?

Authors:  P A Bardsley
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

Review 7.  Obstructive sleep apnea-pathogenesis and treatment.

Authors:  M H Gotfried; S F Quan
Journal:  Lung       Date:  1984       Impact factor: 2.584

8.  Obstructive sleep apnoea syndrome.

Authors:  J R Stradling
Journal:  Br Med J (Clin Res Ed)       Date:  1982-08-21

9.  Protriptyline treatment of sleep hypoxaemia in Duchenne muscular dystrophy.

Authors:  P E Smith; R H Edwards; P M Calverley
Journal:  Thorax       Date:  1989-12       Impact factor: 9.139

10.  Flow-volume curves and sleep-disordered breathing: therapeutic implications.

Authors:  E F Haponik; P L Smith; J Kaplan; E R Bleecker
Journal:  Thorax       Date:  1983-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.